|
|||||
![]() |
|
Scientific consulting firm Exponent (NASDAQ:EXPO) announced better-than-expected revenue in Q1 CY2025, but sales were flat year on year at $137.4 million. On the other hand, next quarter’s revenue guidance of $130 million was less impressive, coming in 0.6% below analysts’ estimates. Its non-GAAP profit of $0.63 per share was 20.4% above analysts’ consensus estimates.
Is now the time to buy EXPO? Find out in our full research report (it’s free).
Exponent’s first quarter performance was shaped by a stable mix of demand across its reactive and proactive consulting services, with management highlighting continued strength in litigation-driven work. CEO Catherine Corrigan pointed out that while technical staff headcount began the year below typical levels due to prior resource alignment, sequential hiring and high utilization rates helped maintain revenue stability. Corrigan noted, “Exponent’s first quarter results exceeded expectations, reinforcing both the resilience of our diversified business model and the value we deliver.”
Looking ahead, management cited macroeconomic uncertainty and client caution as drivers of a softer revenue outlook. CFO Rich Schlenker explained that some clients are delaying proactive projects, especially in regulated and consumer sectors, and that utilization rates will be affected by holiday timing and ongoing project delays. Corrigan emphasized that Exponent remains focused on hiring in areas with robust demand, particularly in advanced vehicle technology and digital health, even as clients navigate shifting supply chains and regulatory challenges.
Exponent’s leadership attributed its flat year-over-year revenue to steady demand for its dispute-focused (reactive) services and a modest decline in proactive consulting. Forward guidance was influenced by client caution and timing-related project delays.
Management sees the coming quarters defined by a mix of industry transformation, regulatory complexity, and shifting client priorities, all set against a backdrop of macroeconomic uncertainty.
In the coming quarters, we will watch closely for (1) signs that delayed proactive projects—especially in consumer electronics and regulatory consulting—resume as client confidence improves, (2) continued sequential growth in technical headcount and utilization as hiring ramps up, and (3) evidence that supply chain realignments and regulatory shifts translate into new advisory work. The persistence of litigation-driven demand and Exponent’s ability to navigate changing regulatory frameworks will also be key indicators of execution.
Exponent currently trades at a forward P/E ratio of 37.9×. At this valuation, is it a buy or sell post earnings? Find out in our free research report.
Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.
While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
May-15 | |
May-02 | |
May-01 | |
May-01 | |
May-01 | |
May-01 | |
May-01 | |
Apr-29 | |
Apr-28 | |
Apr-26 | |
Apr-16 | |
Apr-10 | |
Mar-20 | |
Mar-19 | |
Mar-18 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite